Home » Stocks » FibroGen

FibroGen, Inc. (FGEN)

Stock Price: $44.21 USD -0.90 (-2.00%)
Updated Aug 14, 2020 4:00 PM EDT - Market closed
After-hours: $44.20 -0.01 (-0.02%) Aug 14, 7:39 PM

Stock Price Chart

Key Info

Market Cap 3.99B
Revenue (ttm) 108.44M
Net Income (ttm) -311.22M
Shares Out 89.10M
EPS (ttm) -3.54
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 14, 2020
Last Price $44.21
Previous Close $45.11
Change ($) -0.90
Change (%) -2.00%
Day's Open 45.29
Day's Range 43.77 - 45.29
Day's Volume 538,404
52-Week Range 22.65 - 48.95

More Stats

Market Cap 3.99B
Enterprise Value 3.35B
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 89.10M
Float 83.84M
EPS (basic) -3.54
EPS (diluted) -3.54
FCF / Share 0.14
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 0.32%
Payout Ratio n/a
Shares Short 7.48M
Short Ratio 14.56
Short % of Float 9.01%
Beta 1.54
PE Ratio n/a
Forward PE n/a
P/FCF Ratio 309.37
PS Ratio 36.84
PB Ratio 10.29
Revenue 108.44M
Operating Income -319.50M
Net Income -311.22M
Free Cash Flow 12.91M
Net Cash 640.78M
Net Cash / Share 7.09
Gross Margin 42.57%
Operating Margin -294.64%
Profit Margin -287.00%
FCF Margin 11.91%
ROA -23.18%
ROE -58.53%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (9)

Buy 5
Overweight 0
Hold 4
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$60.88*
(37.71% upside)
Low
44.0
Current: $44.21
High
84.0
Target: 60.88
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue25721313118318113810265.93
Revenue Growth20.48%62.57%-28.49%1.31%31.41%34.68%54.96%-
Gross Profit25521313118318113810265.93
Operating Income-89.31-86.69-117-50.04-77.63-50.10-7.95-27.22
Net Income-76.97-86.42-121-58.07-85.78-59.50-14.94-32.57
Shares Outstanding86.6384.0672.9962.7460.3418.7813.1913.13
Earnings Per Share-0.89-1.03-1.66-0.93-1.42-3.17-1.13-2.48
Operating Cash Flow-78.71-76.14-66.517.11-18.5722.4125.92-5.61
Capital Expenditures-5.76-7.84-8.50-1.25-1.98-8.11-6.80-0.74
Free Cash Flow-84.46-83.98-75.015.86-20.5514.3119.11-6.35
Cash & Equivalents53462173625318118713047.14
Total Debt51.1097.1697.7697.3597.0496.8296.8193.23
Net Cash / Debt48352463815684.1390.2633.25-46.09
Assets857881899470471484297266
Liabilities322352351294274243189143
Book Value516509528156178221-88.71-73.95
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name FibroGen, Inc.
Country United States
Employees 531
CEO Enrique A. Conterno

Stock Information

Ticker Symbol FGEN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: FGEN
IPO Date November 14, 2014

Description

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. The company is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase II trial for the treatment of Duchenne muscular dystrophy. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.